440 related articles for article (PubMed ID: 29532760)
1. Efficacy and Safety of Autologous Cell-based Therapy in Patients with No-option Critical Limb Ischaemia: A Meta-Analysis.
Wahid FSA; Ismail NA; Wan Jamaludin WF; Muhamad NA; Mohamad Idris MA; Lai NM
Curr Stem Cell Res Ther; 2018; 13(4):265-283. PubMed ID: 29532760
[TBL] [Abstract][Full Text] [Related]
2. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.
Abdul Wahid SF; Ismail NA; Wan Jamaludin WF; Muhamad NA; Abdul Hamid MKA; Harunarashid H; Lai NM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010747. PubMed ID: 30155883
[TBL] [Abstract][Full Text] [Related]
3. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials.
Teraa M; Sprengers RW; van der Graaf Y; Peters CE; Moll FL; Verhaar MC
Ann Surg; 2013 Dec; 258(6):922-9. PubMed ID: 23426345
[TBL] [Abstract][Full Text] [Related]
4. Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation.
Hernández P; Cortina L; Artaza H; Pol N; Lam RM; Dorticós E; Macías C; Hernández C; del Valle L; Blanco A; Martínez A; Díaz F
Atherosclerosis; 2007 Oct; 194(2):e52-6. PubMed ID: 16982058
[TBL] [Abstract][Full Text] [Related]
5. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia.
Moazzami K; Moazzami B; Roohi A; Nedjat S; Dolmatova E
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD008347. PubMed ID: 25525690
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia - The SCELTA Trial.
Liotta F; Annunziato F; Castellani S; Boddi M; Alterini B; Castellini G; Mazzanti B; Cosmi L; Acquafresca M; Bartalesi F; Dilaghi B; Dorigo W; Graziani G; Bartolozzi B; Bellandi G; Carli G; Bartoloni A; Fargion A; Fassio F; Fontanari P; Landini G; Lucente EAM; Michelagnoli S; Orsi Battaglini C; Panigada G; Pigozzi C; Querci V; Santarlasci V; Parronchi P; Troisi N; Baggiore C; Romagnani P; Mannucci E; Saccardi R; Pratesi C; Gensini G; Romagnani S; Maggi E
Circ J; 2018 May; 82(6):1688-1698. PubMed ID: 29576595
[TBL] [Abstract][Full Text] [Related]
7. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia.
Gupta PK; Chullikana A; Parakh R; Desai S; Das A; Gottipamula S; Krishnamurthy S; Anthony N; Pherwani A; Majumdar AS
J Transl Med; 2013 Jun; 11():143. PubMed ID: 23758736
[TBL] [Abstract][Full Text] [Related]
8. Autologous bone marrow mononuclear cell therapy improves symptoms in patients with end-stage peripheral arterial disease and reduces inflammation-associated parameters.
Malyar NM; Radtke S; Malyar K; Arjumand J; Horn PA; Kröger K; Freisinger E; Reinecke H; Giebel B; Brock FE
Cytotherapy; 2014 Sep; 16(9):1270-9. PubMed ID: 24972744
[TBL] [Abstract][Full Text] [Related]
9. Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.
Higashi Y; Miyazaki M; Goto C; Sanada H; Sueda T; Chayama K
J Cardiovasc Pharmacol; 2010 Jan; 55(1):56-61. PubMed ID: 19834330
[TBL] [Abstract][Full Text] [Related]
10. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia.
Moazzami K; Majdzadeh R; Nedjat S
Cochrane Database Syst Rev; 2011 Dec; (12):CD008347. PubMed ID: 22161427
[TBL] [Abstract][Full Text] [Related]
11. Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia.
Moazzami B; Mohammadpour Z; Zabala ZE; Farokhi E; Roohi A; Dolmatova E; Moazzami K
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008347. PubMed ID: 35802393
[TBL] [Abstract][Full Text] [Related]
12. Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience.
Subrammaniyan R; Amalorpavanathan J; Shankar R; Rajkumar M; Baskar S; Manjunath SR; Senthilkumar R; Murugan P; Srinivasan VR; Abraham S
Cytotherapy; 2011 Sep; 13(8):993-9. PubMed ID: 21671823
[TBL] [Abstract][Full Text] [Related]
13. Use of autologous bone marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease.
Franz RW; Parks A; Shah KJ; Hankins T; Hartman JF; Wright ML
J Vasc Surg; 2009 Dec; 50(6):1378-90. PubMed ID: 19837539
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of granulocyte-colony-stimulating factor administration following autologous intramuscular implantation of bone marrow mononuclear cells: a randomized controlled trial in patients with advanced lower limb ischemia.
Zafarghandi MR; Ravari H; Aghdami N; Namiri M; Moazzami K; Taghiabadi E; Fazel A; Pournasr B; Farrokhi A; Sharifian RA; Salimi J; Moini M; Baharvand H
Cytotherapy; 2010 Oct; 12(6):783-91. PubMed ID: 20078390
[TBL] [Abstract][Full Text] [Related]
15. Relationship between cell number and clinical outcomes of autologous bone-marrow mononuclear cell implantation in critical limb ischemia.
Yusoff FM; Kajikawa M; Takaeko Y; Kishimoto S; Hashimoto H; Maruhashi T; Nakashima A; Wahid SFSA; Higashi Y
Sci Rep; 2020 Nov; 10(1):19891. PubMed ID: 33199760
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia.
Madaric J; Klepanec A; Valachovicova M; Mistrik M; Bucova M; Olejarova I; Necpal R; Madaricova T; Paulis L; Vulev I
Stem Cell Res Ther; 2016 Aug; 7(1):116. PubMed ID: 27530339
[TBL] [Abstract][Full Text] [Related]
17. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells.
Arango-Rodríguez ML; Mateus LC; Sossa CL; Becerra-Bayona SM; Solarte-David VA; Ochoa Vera ME; Viviescas LTG; Berrio AMV; Serrano SE; Vargas O; Isla AC; Benitez A; Rangel G
Stem Cell Res Ther; 2023 Aug; 14(1):221. PubMed ID: 37626416
[TBL] [Abstract][Full Text] [Related]
18. Autologous bone marrow stem cell transplantation in critical limb ischemia: a meta-analysis of randomized controlled trials.
Liu FP; Dong JJ; Sun SJ; Gao WY; Zhang ZW; Zhou XJ; Yang L; Zhao JY; Yao JM; Liu M; Liao L
Chin Med J (Engl); 2012 Dec; 125(23):4296-300. PubMed ID: 23217403
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease.
Idei N; Soga J; Hata T; Fujii Y; Fujimura N; Mikami S; Maruhashi T; Nishioka K; Hidaka T; Kihara Y; Chowdhury M; Noma K; Taguchi A; Chayama K; Sueda T; Higashi Y
Circ Cardiovasc Interv; 2011 Feb; 4(1):15-25. PubMed ID: 21205941
[TBL] [Abstract][Full Text] [Related]
20. Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products.
Tournois C; Pignon B; Sevestre MA; Al-Rifai R; Creuza V; Poitevin G; François C; Nguyen P
Cytotherapy; 2017 Feb; 19(2):299-310. PubMed ID: 27914820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
